Karyopharm Therapeutics Inc. KPTI
1.62
(0.11)
(6.36%)
as of 25 Sep
- Market cap
- $39.2M
- P/E
- 0.0×
Follow KPTI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 78.98% | 82.70% | 81.86% | 58.11% |
+8 more TTM periods Free account |
|
| (207.90%) | (150.48%) | (143.71%) | (87.24%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
809.55% | (2,137.35%) | (1,751.91%) | (4,596.86%) | |
Average Days of Receivables |
74.36 | 56.41 | 65.42 | 81.63 | |
Free Cash Flow per Share |
(2.26) | (2.69) | (6.89) | (10.31) | |
Free Cash Flow |
(65.35) | (59.11) | (75.37) | (89.35) | |
Piotroski F-Score |
2.00 | 2.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
432.13% | (119.20%) | 3,295.54% | 263.67% | |
Accounts Receivable Turnover |
4.67 | 5.16 | 5.13 | 4.48 | |
Accounts Payable Turnover |
1.18 | 1.18 | 1.31 | 1.04 | |
Inventory Turnover |
1.34 | 1.43 | 1.36 | 1.34 | |
Average Days of Payables |
463.90 | 260.61 | 245.60 | 339.56 | |
Days of Inventory on Hand |
241.88 | 219.19 | 247.75 | 249.76 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
82.50% | 82.58% | 86.00% | 92.09% | |
Selling, General and Administrative Expense of Revenue |
69.55% | 69.18% | 72.03% | 76.91% | |
Share Based Compensation of Revenue |
7.94% | 8.93% | 9.62% | 9.83% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.29 | 0.30 | 0.38 | 0.72 | |
Depreciation/Fixed assets |
108.29 | 114.21 | 100.31 | 82.16 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
5.07 | 6.86 | 13.36 | 16.44 | |
Operating CF per Share |
(2.26) | (2.69) | (6.89) | (10.31) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(153.28%) | (129.02%) | (134.21%) | (87.43%) |
Columns are period end dates